Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 490

1.

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.

Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME.

Headache. 2018 Nov 18. doi: 10.1111/head.13446. [Epub ahead of print]

PMID:
30450545
2.

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.

Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; COL MIG-301 Study Group.

Neurology. 2018 Nov 16. pii: 10.1212/WNL.0000000000006641. doi: 10.1212/WNL.0000000000006641. [Epub ahead of print]

PMID:
30446595
3.

A fluorescence nanoscopy marker for corticotropin-releasing hormone type 1 receptor: computer design, synthesis, signaling effects, super-resolved fluorescence imaging, and in situ affinity constant in cells.

Szalai AM, Armando NG, Barabas FM, Stefani FD, Giordano L, Bari SE, Cavasotto CN, Silberstein S, Aramendía PF.

Phys Chem Chem Phys. 2018 Nov 14. doi: 10.1039/c8cp06196c. [Epub ahead of print]

PMID:
30427333
4.

Basic Considerations for the Use of Monoclonal Antibodies in Migraine.

Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E.

Headache. 2018 Nov 13. doi: 10.1111/head.13439. [Epub ahead of print]

PMID:
30426478
5.

Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.

Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM.

Headache. 2018 Oct 30. doi: 10.1111/head.13421. [Epub ahead of print]

PMID:
30375650
6.

From LBR-101 to Fremanezumab for Migraine.

Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E.

CNS Drugs. 2018 Nov;32(11):1025-1037. doi: 10.1007/s40263-018-0579-4. Review.

PMID:
30311143
7.

Erenumab in the treatment of migraine.

Jain S, Yuan H, Spare N, Silberstein SD.

Pain Manag. 2018 Sep 21. doi: 10.2217/pmt-2018-0037. [Epub ahead of print]

PMID:
30235976
8.

Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review.

Lauritsen CG, Silberstein SD.

Cephalalgia. 2018 Aug 23:333102418796781. doi: 10.1177/0333102418796781. [Epub ahead of print]

PMID:
30139273
9.

Ketamine for Refractory Headache: A Retrospective Analysis.

Schwenk ES, Dayan AC, Rangavajjula A, Torjman MC, Hernandez MG, Lauritsen CG, Silberstein SD, Young W, Viscusi ER.

Reg Anesth Pain Med. 2018 Nov;43(8):875-879. doi: 10.1097/AAP.0000000000000827.

PMID:
29923953
10.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

PMID:
29800211
11.

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.

Frampton JE, Silberstein S.

Drugs. 2018 Apr;78(6):715. doi: 10.1007/s40265-018-0906-6.

12.

The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders.

Berk T, Silberstein SD.

Headache. 2018 May;58(5):783-789. doi: 10.1111/head.13298. Epub 2018 Mar 14.

PMID:
29536530
13.

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.

Frampton JE, Silberstein S.

Drugs. 2018 Apr;78(5):589-600. doi: 10.1007/s40265-018-0894-6. Erratum in: Drugs. 2018 Apr 20;:.

14.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

15.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
16.

Preventive Therapies for Chronic Migraine.

Silberstein SD, Yeung PP, Aycardi E.

N Engl J Med. 2018 Feb 22;378(8):774. doi: 10.1056/NEJMc1716990. No abstract available.

PMID:
29466162
17.

Current management: migraine headache.

Silberstein SD.

CNS Spectr. 2017 Dec;22(S1):1-13. doi: 10.1017/S1092852917000864.

PMID:
29350125
18.

Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.

Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC.

J Am Coll Cardiol. 2017 Dec 5;70(22):2766-2774. doi: 10.1016/j.jacc.2017.09.1105.

PMID:
29191325
19.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

20.

The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations.

Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ.

Am J Manag Care. 2017 Nov;23(17 Suppl):S326-S333.

21.

CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.

Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD.

BioDrugs. 2017 Dec;31(6):487-501. doi: 10.1007/s40259-017-0250-5. Review.

PMID:
29116598
22.

AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.

Lipton RB, McGinley JS, Shulman KJ, Silberstein SD, Wirth RJ, Buse DC.

Headache. 2018 Feb;58(2):229-242. doi: 10.1111/head.13199. Epub 2017 Oct 16.

PMID:
29034453
23.

A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.

Silberstein SD.

Expert Opin Drug Saf. 2018 Jan;17(1):89-97. doi: 10.1080/14740338.2018.1390563. Epub 2017 Oct 20. Review.

PMID:
28994319
24.

Histamine and Migraine.

Yuan H, Silberstein SD.

Headache. 2018 Jan;58(1):184-193. doi: 10.1111/head.13164. Epub 2017 Sep 1.

PMID:
28862769
25.

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.

Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.

Neurology. 2017 Sep 19;89(12):1237-1243. doi: 10.1212/WNL.0000000000004391. Epub 2017 Aug 23.

PMID:
28835404
26.

Endocrinology and the brain: corticotropin-releasing hormone signaling.

Inda C, Armando NG, Dos Santos Claro PA, Silberstein S.

Endocr Connect. 2017 Aug;6(6):R99-R120. doi: 10.1530/EC-17-0111. Epub 2017 Jul 14. Review.

27.

AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine.

Silberstein S.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):821-832. doi: 10.1080/17512433.2017.1339600. Epub 2017 Jul 3. Review.

PMID:
28605258
28.

cAMP-dependent cell differentiation triggered by activated CRHR1 in hippocampal neuronal cells.

Inda C, Bonfiglio JJ, Dos Santos Claro PA, Senin SA, Armando NG, Deussing JM, Silberstein S.

Sci Rep. 2017 May 16;7(1):1944. doi: 10.1038/s41598-017-02021-7.

29.

Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan.

Silberstein S, Winner PK, McAllister PJ, Tepper SJ, Halker R, Mahmoud RA, Siffert J.

Headache. 2017 Jun;57(6):862-876. doi: 10.1111/head.13105. Epub 2017 May 11.

PMID:
28497569
30.

Neuropeptides.

Silberstein SD.

Headache. 2017 May;57 Suppl 2:35-36. doi: 10.1111/head.13093. No abstract available.

PMID:
28485847
31.

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R.

Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28.

PMID:
28460892
32.

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes.

Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ.

Headache. 2017 May;57(5):766-777. doi: 10.1111/head.13074. Epub 2017 Apr 6.

33.

Topiramate in Migraine Prevention: A 2016 Perspective.

Silberstein SD.

Headache. 2017 Jan;57(1):165-178. doi: 10.1111/head.12997. Epub 2016 Nov 30. Review.

PMID:
27902848
34.

Characterization of a Protein Interactome by Co-Immunoprecipitation and Shotgun Mass Spectrometry.

Maccarrone G, Bonfiglio JJ, Silberstein S, Turck CW, Martins-de-Souza D.

Methods Mol Biol. 2017;1546:223-234.

PMID:
27896772
35.

Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study.

Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, Rubenstein Engel E, Tepper SJ; ACT1 Study Group.

Headache. 2016 Sep;56(8):1317-32. doi: 10.1111/head.12896.

36.

The American Headache Society Cluster Guidelines.

Silberstein SD.

Headache. 2016 Jul;56(7):1091-2. doi: 10.1111/head.12867. No abstract available.

PMID:
27432622
37.

Inhaled drug therapy development for the treatment of migraine.

Chua AL, Silberstein S.

Expert Opin Pharmacother. 2016 Sep;17(13):1733-43. doi: 10.1080/14656566.2016.1203901. Epub 2016 Jul 28. Review.

PMID:
27416108
38.

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR; EVENT Study Group.

Neurology. 2016 Aug 2;87(5):529-38. doi: 10.1212/WNL.0000000000002918. Epub 2016 Jul 13.

39.

Different cAMP sources are critically involved in G protein-coupled receptor CRHR1 signaling.

Inda C, Dos Santos Claro PA, Bonfiglio JJ, Senin SA, Maccarrone G, Turck CW, Silberstein S.

J Cell Biol. 2016 Jul 18;214(2):181-95. doi: 10.1083/jcb.201512075. Epub 2016 Jul 11.

40.

The migraine postdrome: An electronic diary study.

Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ.

Neurology. 2016 Jul 19;87(3):309-13. doi: 10.1212/WNL.0000000000002789. Epub 2016 Jun 22.

41.

Botulinum neurotoxin type-A when utilized in animals with trigeminal sensitization induced a antinociceptive effect.

Piovesan EJ, Oshinsky M, Silberstein S, Kowacs PA, Novak EM, Werneck LC.

Arq Neuropsiquiatr. 2016 Jun;74(6):462-9. doi: 10.1590/0004-282X20160067.

42.

How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine.

Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S.

Headache. 2016 Jul;56(7):1194-200. doi: 10.1111/head.12870. Epub 2016 Jun 20.

PMID:
27322907
43.

The Management of Adults With Acute Migraine in the Emergency Department.

Silberstein S.

Headache. 2016 Jun;56(6):907-8. doi: 10.1111/head.12865. No abstract available.

PMID:
27300481
44.

Considerations for management of migraine symptoms in the primary care setting.

Silberstein SD.

Postgrad Med. 2016 Jun;128(5):523-37. doi: 10.1080/00325481.2016.1175912. Epub 2016 May 10. Review.

PMID:
27078039
45.

Erratum to: Targeting CGRP: A New Era for Migraine Treatment.

Wrobel Goldberg S, Silberstein SD.

CNS Drugs. 2016 Apr;30(4):355. No abstract available.

PMID:
27067342
46.

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.

Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R.

Lancet Neurol. 2016 Apr;15(4):382-90. doi: 10.1016/S1474-4422(16)00019-3. Epub 2016 Feb 12.

PMID:
26879279
47.

The Use of Botulinum Toxin in the Management of Headache Disorders.

Silberstein SD.

Semin Neurol. 2016 Feb;36(1):92-8. doi: 10.1055/s-0036-1571443. Epub 2016 Feb 11.

PMID:
26866501
48.

Long-Term Pain Reduction Does Not Imply Improved Functional Outcome in Patients Treated With Combined Supraorbital and Occipital Nerve Stimulation for Chronic Migraine.

Clark SW, Wu C, Boorman DW, Chalouhi N, Zanaty M, Oshinsky M, Young WB, Silberstein SD, Sharan AD.

Neuromodulation. 2016 Jul;19(5):507-14. doi: 10.1111/ner.12400. Epub 2016 Feb 10.

PMID:
26861893
49.

Case Report: Secondary SUNCT After Radiation Therapy--A Novel Presentation.

Berk T, Silberstein S.

Headache. 2016 Feb;56(2):397-401. doi: 10.1111/head.12736. Epub 2015 Dec 8. No abstract available.

PMID:
26643474
50.

Single-item migraine screening tests, self-reported bothersome headache or stripe pattern hypersensitivity?

Yuan H, Hopkins M, Goldberg JD, Silberstein SD.

Acta Neurol Scand. 2016 Oct;134(4):277-83. doi: 10.1111/ane.12539. Epub 2015 Dec 1.

PMID:
26626126

Supplemental Content

Loading ...
Support Center